PMI appoints Matthew Holman as Vice President of Regulatory Strategy

PMI appoints Matthew Holman as Vice President of Regulatory Strategy
Matthew Holman leaves FDA role to become PMI's US Science Engagement and Regulatory Strategy VP as the company seeks to promote safer nicotine alternatives.

Matthew Holman has left his position at the FDA to become the Vice President of Scientific Engagement and Regulatory Strategy for PMI in the United States.

Of course, considering the tobacco companies are currently facing strict regulations and public scrutiny, these appointments are crucial. Badrul Chowdhury, who has worked at the FDA for over 20 years, has accepted the position of Chief Life Sciences Officer, while Matthew Holman has been appointed as Vice President of Science Engagement and Regulatory Strategy for the tobacco company in the United States.

In recent years, Philip Morris International (PMI) has been making efforts to improve its image and reputation by turning towards the sale of safer nicotine alternatives. Former CEO Andre Catantzopoulos believed that a smokeless future is possible and that achieving a consensus with the government and society is necessary through proper supervision and regulation. He stated that alternative nicotine products can be a part of effective tobacco policy. "Thanks to rapid progress in science and technology, and PMI's firm commitment, these products have now become a reality," he said.

Although current CEO of PMI, Jacek Olczak, has stated that the tobacco company intends to achieve its goal of 50% smoke-free product sales by 2025, he also claims the company is fully capable of replacing cigarettes with safer alternatives. "We have a leading portfolio of traditional and smoke-free tobacco products, an excellent management team, and an agile, efficient, and quick-learning organization. We are fully capable of continuing to succeed in our vision of replacing cigarettes with better alternatives for the benefit of consumers, shareholders, and society," he stated earlier this year, quoted by The Edge.

PMI is working hard to change its image.

Last year, PMI received criticism from the British Asthma Association and British Lung Foundation for their collaboration with asthma inhaler manufacturer Vectura. This move appeared hypocritical, as the investment was in a product that could help treat tobacco-related diseases.

Meanwhile, Altria has recently reiterated its plan to enter the healthcare field, stating that this is a natural evolution for tobacco companies. "This is a natural evolution for PMI to further transform our business into a more holistic lifestyle, consumer health, and healthcare company in the future. This evolution is not only fulfilling our continued commitment to a smoke-free future but also fulfilling the development and commercialization of scientifically validated products and solutions to meet unmet consumer and patient needs.

The market for health and wellness products is vast and constantly expanding. We have several key areas of focus in our pipeline. For consumers and over-the-counter healthcare products, we have several initiatives focused on concentration, sleep, energy, pain relief, and calmness. In the healthcare field, we believe that patients' demand for fast and effective treatments for cardiovascular diseases such as myocardial infarction and neurological conditions such as migraines has yet to be met, and innovative solutions can meet these needs. We recently accelerated this part of our strategy through the acquisition of Vectura, an innovative inhalation delivery solution provider, and Fertin, a leading developer and manufacturer of innovative drugs and healthcare products based on oral and intraoral delivery systems," said Alzack.


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.

This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The compilation of this article is solely for communication and research within the industry.

Due to limitations in translation abilities, the translated article may not fully express the original text, so please refer to the original text for accuracy.

2FIRSTS maintains complete alignment with the Chinese government in regards to any statements or positions relating to domestic issues, Hong Kong, Macau, Taiwan, and foreign affairs.

The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.